Creative Biolabs ADC Blog

Menu

Skip to content
  • Home
  • Antibody-drug Conjugates Research
  • Antibody-drug Conjugates Manufacturing
  • News

Category Archives: Antibody-drug Conjugates Research

01Mar/18

Phase 2 Data for Roche’s Lymphoma ADC Doesn’t Disappoint

March 1, 2018Antibody-drug Conjugates Research, Newsantibody drug conjugates, fdabioadc

With breakthrough designation from the FDA and priority medicine status in the EU, expectations for Roche’s antibody-drug conjugate for non-Hodgkin lymphoma polatuzumab vedotin are running pretty high. Phase 2 data presented atRead More…

08Feb/18

AMID Significant Progress, Robust Growth and Advancing Pipeline — Immunogen Closes Massachusetts Facility

February 8, 2018Antibody-drug Conjugates Research, Newsantibody drug conjugate pepline, antibody drug conjugatesbioadc

A leader in the expanding field of antibody-drug conjugates or ADCs for the treatment of cancer, Immunogen last week highlighted some of the company’s the operating results for 2017. Immunogen is a clinical-stage biotechnologyRead More…

Posts navigation

  • « Previous
  • 1
  • 2
  • 3
  • 4

Categories

Recent Posts

  • The Era of the “Biological Missile”: Innovations and Frontiers in Antibody-Drug Conjugate Development
  • Targeting Drug-Resistant Breast Cancer with a Novel ADC
  • Aptamer-Drug Conjugates: The Next Frontier in Targeted Cancer Therapy Shows Encouraging Results
  • A New Hope for Cancer Therapy: How ADCs are Redefining Treatment
  • Hyaluronidase-Conjugated Liposomes May Effectively Target Pancreatic Cancer

Archives

Contact Us

USA - UK

Copyright © Creative Biolabs ADC Blog
Powered by WordPress , Theme i-max by TemplatesNext.
MENU
  • Home
  • Antibody-drug Conjugates Research
  • Antibody-drug Conjugates Manufacturing
  • News